Transcript VTE Updates on Measures and Improvment Strategies - K

VENOUS THROMBOEMBOLISM
INPATIENT QUALITY MEASURES
HOWARD SHAPS, MD, MBA
MEDICAL DIRECTOR
HEALTH CARE EXCEL
MARCH 5, 2013
AGENDA
• Background
• Sub-populations
• Measures with exclusions and documentation requirements
• Quality Improvement
2
VENOUS THROMBOEMBOLISM (VTE)
• New measure set that becomes a mandatory submission
• Beginning with January 1, 2013 discharges
• Developed via a project between the Joint Commission (TJC) and the National
Quality Forum (NQF)
• Measures have been tested and extensively studied
• Final measures endorsed by the NQF (National Quality Forum) in 2008
3
VENOUS THROMBOEMBOLISM (VTE)
• Measures align with the Centers for Medicare & Medicaid Services
(CMS) quality initiatives
• Hospital Compare
• VTE measures will be posted December 2013
• Hospitals that do not report required quality data
• At risk for losing 2% of payments by CMS
• Private payers likely to follow
4
5
VTE SUB-POPULATIONS
1. No VTE Sub-Population
• Patients with no ICD-9-CM Principal or Other Diagnosis Code as defined in
Appendix A, Tables 7.02, 7.03 and 7.04
• Patient Age (Admission Date minus Birthdate) greater than or equal to 18 years
• Length of Stay (Discharge Date minus Admission Date) less than or equal to 120
days
6
VTE SUB-POPULATIONS
2. Principal VTE sub-population
• Patients with an ICD-9-CM Principal Diagnosis Code as defined in Appendix A,
Tables 7.03 and 7.04
• Patient Age (Admission Date minus Birthdate) greater than or equal to 18 years
• Length of Stay (Discharge Date minus Admission Date) less than or equal to 120
days
7
VTE SUB-POPULATIONS
3. Other VTE Only sub-population
• Patients with an ICD-9-CM Other Diagnosis Code as defined in Appendix A, Tables
7.03 and 7.04
• Patient Age (Admission Date minus Birthdate) greater than or equal to 18 years
• Length of Stay (Discharge Date minus Admission Date) less than or equal to 120
days
• The patients cannot have a ICD-9-CM Principal Diagnosis Code as defined in
Appendix A, Tables 7.03 and 7.04
8
VTE MEASURES
• VTE – 1 Venous Thromboembolism Prophylaxis
• VTE – 2 Intensive Care Unit Venous Thromboembolism Prophylaxis
• VTE - 3 Venous Thromboembolism Patients with Anticoagulation Overlap Therapy
• VTE – 4 Venous Thromboembolism Patients Receiving Unfractionated Heparin with
Dosages/Platelet Count Monitoring by Protocol or Nomogram
• VTE – 5 Venous Thromboembolism Warfarin Therapy Discharge Instructions
• VTE – 6 Hospital Acquired Potentially-Preventable Venous Thromboembolism
9
VTE Sub - Populations
2 – Principal VTE
1 - No VTE
VTE 3,
4, and 5
3 – Other VTE
VTE 1 and 2
VTE 6
10
11
Bob May
12
VTE - 1
VTE Prophylaxis
13
VTE - 1 DESCRIPTION
• This measure assesses:
• The number of patients who received VTE prophylaxis, OR
• Have documentation why no VTE prophylaxis was given
• The day of or the day after hospital admission OR surgery end date, for
surgeries that start the day of OR the day after hospital admission
14
VTE – 1 RATIONALE
• Hospitalized patients at high-risk for VTE may develop an
asymptomatic deep vein thrombosis (DVT), and die from pulmonary
embolism (PE) even before the diagnosis is suspected
• The majority of fatal events occur as sudden or abrupt death
• It is expected that all medical and surgical patients will receive some
form of VTE prophylaxis
• More than 2 million Americans develop a VTE each year1
1www.arqh.gov
15
VTE – 1 RATIONALE
• Approximately two-thirds of cases of DVT or PE are associated with
recent hospitalization
• 30 days post hospitalization
• A recent analysis from the ENDORSE survey, which evaluated
prophylaxis rates in 17,084 major surgery patients….
• Found that more than one third of patients at risk for VTE (38%) did not receive
prophylaxis and that rates varied by surgery type1
• The Agency for Healthcare Research and Quality (ARQH) defined
thromboprophylaxis against VTE as the "number one patient safety
practice" for hospitalized patients
1Cohen
AT, et al. ENDORSE study: a multinational cross-sectional study. Lancet. 2008;371:387-394. 16
VTE – 1 RATIONALE
• Chances of complications from prophylaxis are small
• Prophylaxis is cost-effective
• Benefits outweigh the risks
• Fatal pulmonary emboli are prevented by thromboprophylaxis1
1Geerts
WH, et al. . Prevention of venous thromboembolism.. Chest. 2008; 133:381S-453S.
17
18
VTE – 1 NUMERATOR
• Patients who received VTE prophylaxis or have documentation why no
VTE prophylaxis was given:
• The day of OR the day after hospital admission
• The day of OR the day after surgery end date for surgeries that start the day of OR
the day after hospital admission
• Excluded Populations - None
19
VTE – 1 DENOMINATOR
• All patients
• Excluded Patients
• Patients less than 18
• Patients with LOS less than 120 days
• Patients with Comfort Measures Only
• Documented on day of or after arrival
• Patients enrolled in clinical trials
• Patients directly admitted to the ICU, or transferred to the ICU the day of or the
day after hospital admission with ICU LOS greater than or equal to one day
20
VTE – 1 DENOMINATOR
• Excluded Patients, continued
• Principal diagnosis of Mental Disorders
• Principal diagnosis of Stroke
• These patients should receive prophylaxis other than graduated compression
stockings
• Any diagnosis of Obstetrics, VTE or Obstetrics VTE
• Principle procedure on Surgical Care Improvement Project (SCIP) tables
• Prophylaxis differs
• Cannot be in SCIP VTE and VTE-1
21
22
VTE – 1 REQUIRED PHYSICIAN DOCUMENTATION
• Patient/family refusal
• May be documented by a nurse
• Must be in the same timeframe as prophylaxis
• Refusal of one type of prophylaxis covers all types
• Example - If refuse heparin, no need for the documentation of the refusal of mechanical
prophylaxis
23
VTE – 1 REQUIRED PHYSICIAN DOCUMENTATION
• “No VTE given”
• Cannot only state the condition, alone
• Thrombocytopenia
• Patient has IVC filter
• Acceptable examples
• “Active GI bleed, cannot give Lovenox”
• “Angiomax is sufficient and no VTE prophylaxis is needed”
• “Will not give enoxaparin”
• Must address both types of prophylaxis
24
VTE – 1 REQUIRED PHYSICIAN DOCUMENTATION
• Other methods to document proper prophylaxis
• Comfort Measures Only documented
• Documented on admit day/day after/day after surgery
• Patient received anticoagulants on day of admission for other reasons
• Cannot accept Plavix, Aspirin, Ticlid
• Must be correct order route
• Warfarin stopped due to high INR
25
VTE – 1 FREQUENT MISTAKES
• Patient has a documented contraindication to pharmacologic
prophylaxis
• Mechanical prophylaxis not addressed
• Mechanical prophylaxis started 2 or more days after admission
• Ambulation inferred to be a reason for no prophylaxis
• Need documentation as to why both methods not used
26
Dick Schapp
27
VTE - 2
ICU VTE Prophylaxis
28
VTE – 2 DESCRIPTION
• This measure assesses the number of patients who received VTE
prophylaxis, OR
• Have documentation why no VTE prophylaxis was given
________________________________________________________________
• The day of or the day after the initial admission (or transfer) to the
Intensive Care Unit, OR
• Surgery end date for surgeries that start the day of OR the day after
ICU admission (or transfer)
29
VTE – 2 EXPECTATIONS
• ICU patients will receive some form of VTE prophylaxis
• Except if no overnight stay, OR
• Reason for no VTE prophylaxis given
• Starting on ICU admission date or day after admission
30
31
VTE – 2 RATIONALE
• Criteria for admission to the ICU itself, puts patients at an increased risk
for developing VTE
• Subsequent increased risk of morbidity from PE
• Risk factors can be related to the acute illness present
• Risk factors may be acquired during the ICU admission
• From subsequent medical treatments
• Limitations of mobility
• Presence of central venous lines
• Mechanical ventilation and subsequent pharmacological paralysis
32
VTE – 2 NUMERATOR
• Patients who received VTE prophylaxis, OR have documentation why
no VTE prophylaxis was given
• The day of or the day after ICU admission (or transfer)
• The day of or the day after surgery end date for surgeries that start the day of or
the day after ICU admission (or transfer)
• Excluded populations: None
33
VTE – 2 DENOMINATOR
• Patients directly admitted or transferred to ICU
• Excluded
• Patients less than 18 years of age
• Patients who have a hospital length of stay (LOS) less than two days and greater
than 120 days
• Patients with Comfort Measures Only documented on day of or day after hospital
arrival
• Patients enrolled in clinical trials
34
VTE – 2 DENOMINATOR
• Excluded, continued
• Patients with ICU LOS less than one day without VTE prophylaxis administered
and documentation for no VTE prophylaxis
• Patients with ICD-9-CM Principal or Other Diagnosis Code of Obstetrics or VTE as
defined in Appendix A, Table 7.02, 7.03, or 7.04
• Patients with ICD-9-CM Principal Procedure Code of Surgical Care Improvement
Project (SCIP) VTE selected surgeries as defined in Appendix A, Tables 5.17, 5.19,
5.20, 5.21, 5.22, 5.23, 5.24 that start the day of or the day after ICU admission or
transfer
35
Derrick Thomas
36
www.arqh.gov
37
VTE - 3
VTE Patients with
Anticoagulation Overlap Therapy
38
VTE – 3 DESCRIPTION
• Assesses the number of patients diagnosed with confirmed VTE who
received an overlap of parenteral (intravenous or subcutaneous)
anticoagulation and warfarin therapy
• For patients who received fewer than five days of overlap therapy
• Should be discharged on both medications, OR
• Have a Reason for Discontinuation of Parenteral Therapy
• Overlap therapy should be administered for at least five days
• With an international normalized ratio (INR) greater than or equal to 2 prior to
discontinuation of the parenteral anticoagulation therapy,
• Discharged on both medications, OR
• Have a Reason for Discontinuation of Parenteral Therapy
39
VTE – 3 POPULATION
• Patients with an acute VTE
• Either principal (on arrival) or other diagnosis (in the hospital)
• Appendix A, Table 7.03 VTE
• Appendix A, Table 7.04 Obstetrics VTE
(Patients given Xarelto are excluded)
40
VTE – 3 PARENTERAL ANTICOAGULANTS
• Direct Thrombin Inhibitors:
• Agatroban (Acova), Bivalirudin (Angiomax), Lepirudin (Refludan)
• Low Molecular Weight Heparins (LMWHs):
• Dalteparin (Fragmin), Enoxaparin (Lovenox), Tinzaparin (Innohep)
• Unfractionated Heparin – IV or SQ
• Factor Xa Inhibitor:
• Fondaparinux Sodium (Arixtra)
41
VTE – 3 OVERLAP THERAPY
• Oral Warfarin therapy AND
• Parenteral anticoagulants
• By either IV or subcutaneous route
• Appendix H, Table 2.3
42
43
VTE – 3 RATIONALE
• For patients who present with a confirmed acute VTE, parenteral
anticoagulation is the first line of therapy
• Rapid onset of action
• Warfarin can be initiated on the first day of treatment after the first
dose of a parenteral anticoagulant has been given
• Warfarin has a very slow onset of action
• Cannot be used as mono-therapy for acute VTE
44
VTE – 3 RATIONALE
• Recommendations to overlap parenteral anticoagulation with oral
warfarin therapy in the initial treatment of VTE events
• Based in part on the known effect of warfarin on the coagulation cascade
• The early increase in the INR
• Often reflects the laboratory finding of initial reduction in clotting factors of the
extrinsic pathway of coagulation resulting in prolongation of the INR
• The patient is still at risk of thromboembolic events due to persistent levels of
coagulation factors of the intrinsic pathway and common pathways of coagulation
45
VTE – 3 BEST PRACTICE
• Overlap warfarin with parenteral anticoagulants until
• 5 days of overlap therapy AND
• INR >= 2.0
• If INR < 2.0 after 5 days, continue overlap therapy
• The recommendation that heparins and warfarin overlap for a five-day
period is based on pharmacokinetic, pharmacologic, pathophysiologic,
and clinical evidence1
1Wittkowsky AK.
Why warfarin and heparin need to overlap when treating acute venous thromboembolism. Dis Mon 2005; 51:112-115.
46
VTE – 3 NUMERATOR
• Patients who received overlap therapy (warfarin and parenteral
anticoagulation):
• Five or more days, with an INR greater than or equal to 2 prior to discontinuation
of parenteral therapy, OR
• Five or more days, with an INR less than 2 and discharged on overlap therapy, OR
• Less than five days and discharged on overlap therapy, OR
• With documentation of reason for discontinuation of parenteral therapy, OR
• With documentation of a reason for no overlap therapy
• Excluded: None
47
VTE – 3 DENOMINATOR
• Patients with confirmed VTE who received warfarin
• Discharges with an ICD-9-CM Principal or Other Diagnosis Codes of VTE
as defined in Appendix A, Table 7.03 or 7.04
48
VTE – 3 DENOMINATOR
• Excluded Population
•
•
•
•
•
•
•
•
•
•
Less than 18 years of age
Length of stay greater than 120 days
Comfort Measures Only documented
Patients enrolled in clinical trials
Patients discharged to a health care facility or home for hospice care
Patients who expired
Patients who left against medical advice
Patients discharged to another hospital
Patients without warfarin therapy during hospitalization
Patients without VTE confirmed by diagnostic testing
49
VTE – 3 ACCEPTABLE TESTS
• Venography
• Pelvic, femoral and other lower extremity veins
• Computed Tomography with Contrast
• Chest, abdomen, pelvis, lower extremity veins
• Pulmonary arteriography/angiography
• MRI/MRV
• Chest, abdomen, pelvis, lower extremity veins
• Nuclear Medicine Studies – High probability ONLY
• Compression Ultrasound
50
VTE – 3 CONFIRMATION
• Radiology reports
• Physician documentation stating acceptable VTE location
• Records can come from outside source
• Physician or nurse must document the VTE is present
• Cannot come from billing documentation
51
VTE – 3 ACCEPTABLE LOCATIONS
• Pulmonary Embolism
• Proximal Lower Extremity Veins
• Inferior Vena Cava
• Iliac Veins
• Femoral Veins
• Popliteal Veins
52
VTE – 3 EXCLUSIONS
• Isolated calf vein thrombosis
• Upper extremity thrombosis
• Intracranial thrombosis
• Hepatic, portal, splenic, mesenteric thrombosis
• Renal vein thrombosis
• Ovarian vein thrombosis
• Chronic VTE
53
VTE – 3 OVERLAP THERAPY
• Sample reasons why overlap therapy was not used
• Surgical procedure
• Bleeding complications
• Patient refused overlap therapy
• Sources for overlap therapy
• Physician documentation
• Nursing documentation
• Medication administration record
54
Jimmy Stewart
55
VTE – 4
VTE Patients Receiving
Unfractionated Heparin with
Dosages/Platelet Count Monitoring
by Protocol or Nomogram
56
VTE – 4 DESCRIPTION
• Description:
• Measure assesses the number of patients diagnosed with confirmed VTE who
• Received intravenous (IV) UFH therapy dosages, AND
• Had their platelet counts monitored using defined parameters such as a nomogram or
protocol
57
58
VTE – 4 RATIONALE
• Heparin is commonly involved in adverse drug events
• Sub-therapeutic and supratherapeutic levels can lead to
thromboembolic or bleeding complications that may increase the
patient’s length of stay
• The use of weight-based nomograms has increased the likelihood that
a therapeutic partial prothromboplastin time (aPTT) will be achieved
within the first 24 to 48 hours of therapy
59
VTE – 4 RATIONALE
• Heparin-induced thrombocytopenia (HIT) occurs more commonly in
patients who receive UFH than in those who receive low molecular
weight heparin1
• Platelet counts generally begin to fall 5-10 days after the initiation of
heparin therapy
• Prompt recognition of HIT is important so that heparin can be
discontinued and the risk of venous and arterial thrombosis minimized
• To detect HIT, platelet count monitoring is recommended for all
patients treated with UFH2
.
1Martel,
N., Lee, J., and Wells, P.S. Blood . 2005 June; 106:2710-2715.
2Warkentin
TE, et al. Chest 2008 . Jun; 133(6 Suppl):340S-80S
60
VTE- 4 NUMERATOR
• Patients who have their IV UFH therapy dosages AND platelet counts
monitored according to defined parameters such as a nomogram or
protocol
• Excluded population - None
61
VTE – 4 DENOMINATOR
• Patients with confirmed VTE receiving IV UFH therapy
• ICD-9-CM Principal or Other Diagnosis Codes of VTE as defined in Appendix A, Table
7.03 or 7.04
62
VTE – 4 DENOMINATOR
• Excluded Populations:
•
•
•
•
•
•
•
•
•
•
•
Patients less than 18 years of age
Patients who have a length of stay greater than 120 days
Patients with Comfort Measures Only documented
Patients enrolled in clinical trials
Patients discharged to a health care facility for hospice care
Patients discharged to home for hospice care
Patients who expired
Patients who left against medical advice
Patients discharged to another hospital
Patients without UFH Therapy Administration
Patients without VTE confirmed by diagnostic testing
63
VTE – 4 UFH THERAPY
• IV Heparin only
• Need documentation of administration
• Medication administration record
• Nursing notes
• Emergency Department record
• Progress notes
• Ambulance record – added to sources effective January 2013
64
Heavy - D
65
VTE - 5
VTE Warfarin Therapy Discharge Instructions
66
VTE – 5 DESCRIPTION
• Assesses the number of patients diagnosed with confirmed VTE that
are discharged to home, home care, court/law enforcement or home
on hospice care on warfarin
• With written discharge instructions that address all four criteria:
• Compliance issues,
• Dietary advice,
• Follow-up monitoring, AND
• Information about the potential for adverse drug reactions/interactions
67
VTE – 5 RATIONALE
• In anticoagulation therapy programs, patient education is a vital
component to achieve successful outcomes, and reducing hospital
readmission rates
• Warfarin is commonly involved in adverse drug events
• Subtherapuetic clot formation
• Supratherapeutic hemorrhage
• The use of standardized practices for anticoagulation therapy that
includes patient/caregiver involvement1
• May reduce the risk of adverse drug events
1Van
Walraven, C.,et al. Chest 2006; 129; 1155-1166.
68
VTE – 5 NUMERATOR
• Patients with documentation that they or their caregivers were given
written discharge instructions or other educational material about
warfarin that addressed all of the following:
• Compliance issues
• Dietary advice
• Follow-up monitoring
• Potential for adverse drug reactions and interactions
• Excluded population: None
69
VTE – 5 DENOMINATOR
• Patients with confirmed VTE discharged on warfarin therapy
• Included Populations:
• Discharges with an ICD-9-CM Principal or Other Diagnosis Codes of VTE as defined
in Appendix A, Table 7.03 or 7.04
• Discharged to home, home care or court/law enforcement
• Discharged to home for hospice care
70
VTE – 5 DENOMINATOR
• Excluded Populations:
• Patients less than 18 years of age
• Patients who have a length of stay greater than 120 days
• Patients enrolled in clinical trials
• Patients without Warfarin Prescribed at Discharge
• Patients without VTE confirmed by diagnostic testing
71
VTE – 5 DOCUMENTATION
• Must be written materials to take home
• Oral discussion is not enough
• Can assume a copy was given to the patient if the material has
• Patient’s name
• Medical record number
• Signature – from nurse and patient
• The patient can refuse instructions, but this must be documented
72
VTE – 5 COMPLIANCE ISSUES
• Must advise the importance of both
• Taking warfarin as instructed, AND
• Monitoring warfarin intake with scheduled INR checks
73
VTE – 5 DIETARY ADVICE
• Must advise both of the following
• May consume a “consistent amount” of foods with Vitamin K
• Rather than avoidance of them
• Avoidance of a major change in diet or consulting a health professional before a
change
74
VTE – 5 FOLLOW-UP MONITORING
• Must document the plan to monitor warfarin after discharge
• Office, clinic, home health
• Scheduled date of next INR check
75
VTE – 5 DISCHARGE INSTRUCTIONS ADDRESS
POTENTIAL FOR…
• Adverse Drug Reactions and Interactions
• Required statements
• Diets and medications can affect the INR
• Do not start or stop any medications except on the advice of a physician or
pharmacist
• Warfarin increases the risk of bleeding
76
VTE – 5 ACCEPTABLE FORMATS
• Copy of instructions given
• Require an documentation the patient had a copy to take home
• Signature not required except to show the patient received a copy
• Copy of pre-printed material in the record
• Requires documentation the patient had a copy to take home
• Statement that written instructions were given
• Must be signed by a nurse
• Must list individual areas of instruction
• Beware of empty check boxes (infers not done)
77
Serena Williams
78
VTE – 6
Hospital Acquired Potentially Preventable VTE
79
VTE – 6 DESCRIPTION
• Assesses the number of patients diagnosed with confirmed VTE
during hospitalization (not present at admission)
• Who did not receive VTE prophylaxis between hospital admission, AND
• The day before the VTE diagnostic testing order date
80
81
VTE – 6 RATIONALE
• The incidence of preventable VTE among hospitalized patients is
overwhelming
• Contributes to extended hospital stays and the rising cost of health care
• Zhan 20031
• The second most common medical complication of postoperative patients,
• The second most common cause of excess length of stay, AND
• The third most common cause of excess mortality and excess charges
1Zhan,
C., Miller M.R. Excessive length of stay, charges and mortality attributable to medical injures during hospitalization. JAMA 2003; 290:1868-1874.
82
VTE – 6 RATIONALE
• Preventable VTE is defined as objectively diagnosed Deep Vein
Thrombosis or Pulmonary Emboli that occurred in a setting in which
thromboprophylaxis was indicated but was either1
• Administered inadequately, OR
• Not administered at all
• In spite of formal guidelines, and recommendations for preventative
care, pulmonary embolism is still the most common preventable cause
of death among hospitalized patients2
1Arnold
DM, et al. Chest. 2001 Dec;120(6):1964-71.
R, et al. JAMA 2003; 290:1868-1874.
2Wachter,
83
VTE – 6 NUMERATOR
• Patients who received no VTE prophylaxis prior to the VTE diagnostic
test order date
• Excluded Population: None
84
VTE – 6 DENOMINATOR
• Patients who developed confirmed VTE during hospitalization
• Included: Discharges with an ICD-9-CM Other Diagnosis Codes of VTE
as defined in Appendix A, Table 7.03 or 7.04
85
VTE – 6 DENOMINATOR
• Excluded
Patients less than 18 years of age
Patients who have a length of stay greater than 120 days
Patients with Comfort Measures Only documented
Patients enrolled in clinical trials
Patients with ICD-9-CM Principal Diagnosis Code of VTE as defined in Appendix A,
Table 7.03 or 7.04
• Patients with VTE Present at Admission
• Patients with reasons for not administering mechanical and pharmacologic
prophylaxis
• Patients without VTE confirmed by diagnostic testing
•
•
•
•
•
86
VTE – 6 COMMONLY OVERLOOKED
• Those who often do not receive adequate VTE prophylaxis
• Moderate risk patients
• Emergency admissions
• Conservatively managed patients
87
VTE – 6 AIMING FOR ZERO
• VTE – 6 captures adverse outcomes
• Goal is 0% on this measure
• Numerator
• Those patients who went on to develop a VTE
• Because of no or insufficient prophylaxis
• Patients who develop a VTE despite prophylaxis do NOT count against
the hospital
• Placed in the denominator
88
VTE – 6 PRESENT ON ADMISSION
• Physician, NP, PA must document that the VTE was diagnosed or
suspected on admission
• Patient can be admitted on VTE treatment
• Diagnostic test ordered on admit date
• Cannot document present on admission if past the admission period
89
VTE – 6 DOCUMENTATION
• Physician, PA, NP, Pharmacist
• Must address contraindications to both mechanical and pharmacologic
prophylaxis
• Patient refusal of prophylaxis can be documented by the physician,
nurse, or in the medication administration record
• Must clearly link the reason prophylaxis was not used
• For both types
• Mechanical prophylaxis must address both extremities
90
VTE – 6 DOCUMENTATION
• What does not count as a reason why prophylaxis was not given
• History of bleeding
• Bleeding risk noted in informed consent process
• Reinfusion of blood products through a blood recovery system
• “Patient at low risk for VTE”
• “VTE prophylaxis not needed”
91
92
VTE Prophylaxis: Actual Failure Modes from the University of California,
San Diego Medical Center and Emory University Hospitals
Differing opinions exist on what is appropriate, even among experts.
Noncompliance with mechanical prophylaxis exists.
Platelet monitoring is haphazard when heparin is ordered.
Transfers out of intensive care units may cause VTE prophylaxis to be dropped.
Prophylaxis is stopped at discharge even when risk continues in some patients.
Widely different impressions are held for when it is safe to start anticoagulation
peri-procedure and post trauma
http://www.ahrq.gov/qual/vtguide/vtguide.pdf
93
94
http://www.ahrq.gov/qual/vtguide/vtguide.pdf
95
http://www.ahrq.gov/qual/vtguide/vtguide.pdf
96
Quality Improvement Strategy Category
Specific Ideas for VTE Prevention
Provider education
• Didactic sessions on VTE prevention (e.g., noon
conference or grand rounds)
• Distributed educational materials (e.g., pocket cards
with VTE risk factors)
Provider reminder systems
• Prompts nested within paper admission, transfer, or
post-op order sets supported by VTE risk assessment
as decision support (VTE protocol)
• Prompts using computerized physician order entry
with risk assessment as decision support (VTE
protocol)
• Stickers on charts or posters in order-writing areas
Facilitated relay of clinical data to providers
Alerts to physicians by means other than medical
records (e.g., page, electronic alert, phone call, or email regarding VTE prophylaxis oversights)
Audit and feedback of performance to providers
Feedback of VTE prophylaxis performance to
individual providers or groups of providers with or
without benchmarking to top performers
97
Quality Improvement Strategy Category
Specific Ideas for VTE Prevention
Patient education
Discrete disclosure to patients of increased risk for VTE
(e.g., pamphlets, physician or nurse teaching of patient or
caregiver, closed-circuit television program in patient
rooms)
Organizational or operational change
• Administrative support personnel dedicated to ensure
constant stocking of VTE protocol order sets
• Clinical support personnel dedicated to ensure and
document that mechanical prophylaxis is worn by
patients
• Hospital-wide or unit-specific teams or individuals with
regular responsibility to ensure each patient is receiving
appropriate VTE prophylaxis (e.g., physician, nurse,
pharmacist)
Incentives, regulation, and policy
• Recognition of highest performers
• Financial incentives based on achievement of VTE
prophylaxis performance goals
• Punitive actions for failures to meet minimum
performance (e.g., suspension of privileges)
• Enforced policy mandating use of VTE protocol (e.g.,
“hard stops” in processing of admission, or transfer, that
fail to prescribe VTE prophylaxis)
98
99
CONTACT INFORMATION
Howard Shaps, MD, MBA
Medical Director, Health Care Excel
1941 Bishop Lane
Suite 400
Louisville, Kentucky 40218
[email protected]
502.454.5112 x 2202
This material was prepared by Health Care Excel, the Medicare Quality Improvement Organization for Kentucky, under contract with the Centers for Medicare & Medicaid Services
(CMS), an agency of the U.S. Department of Health and Human Services. The contents presented do not necessarily reflect CMS policy. Created on March 1, 2013
10SOW-KY-INDPAT-13-004
100